Inhibition and stimulation of intestinal and hepatic CYP3A activity: Studies in humanized CYP3A4 transgenic mice using triazolam

Drug Metabolism and Disposition

Volumn 37, Issue 12, 2009, Pages 2305-2313

  Van Waterschoot, Robert A B ^a   Rooswinkel, Rogier W ^a   Sparidans, Rolf W ^a   Van Herwaarden, Antonius E ^a   Beijnen, Jos H ^b,c   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1' HYDROXYTRIAZOLAM; CYTOCHROME P450 3A4; DASATINIB; DRUG METABOLITE; ERLOTINIB; GEFITINIB; IMATINIB; KETOCONAZOLE; SORAFENIB; SUNITINIB; TRIAZOLAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INTESTINE; KNOCKOUT MOUSE; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; INTESTINES; KETOCONAZOLE; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES; QUINAZOLINES; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; TRIAZOLAM;

MUS; MUS MUSCULUS;

EID: 71049142699     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029397     Document Type: Article

References (35)

1. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, and Simantov R (2007) Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 13:2684-2691.
2. Andersson T, Miners JO, Veronese ME, and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137. (Pubitemid 24247754)
3. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, and van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158-6164. (Pubitemid 35244466)
4. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 (Suppl 1):S3-S11.
5. DohertyMMand Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235-253.
6. Dresser GK and Bailey DG (2003) The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 33 (Suppl 2):10-16.
7. Dresser GK, Spence JD, and Bailey DG (2000) Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57. (Pubitemid 30055093)
8. Ekroos M and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-13687. (Pubitemid 44413967)
9. Fujita K, Ando Y, Narabayashi M, Miya T, Nagashima F, Yamamoto W, Kodama K, Araki K, Endo H, and Sasaki Y (2005) Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin but activates that of 7-ethyl-10- [4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan. Drug Metab Dispos 33:1785-1790. (Pubitemid 41697262)
10. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17. (Pubitemid 29222549)
11. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360.
12. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
13. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96. (Pubitemid 19191264)
14. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908. (Pubitemid 29347590)
15. Li J, Zhao M, He P, Hidalgo M, and Baker SD (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737. (Pubitemid 46955138)
16. Lin JH (2000) Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331.
17. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
18. McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, and Hutchison M (2005) Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35:39-50.
19. Obach RS (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81-89.
20. Paine MF and Oberlies NH (2007) Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 3:67-80.
21. Perloff MD, von Moltke LL, Cotreau MM, and Greenblatt DJ (1999) Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. Biochem Pharmacol 57:1227-1232.
22. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628. (Pubitemid 30067425)
23. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198. (Pubitemid 32537001)
24. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
25. Thummel KE (2007) Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117:3173-3176.
26. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430. (Pubitemid 28231501)
27. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381. (Pubitemid 27043473)
28. van Herwaarden AE, van Waterschoot RA, and Schinkel AH (2009) How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol Sci 30:223-227.
29. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
30. van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, and Schinkel AH (2009) Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 23:224-231.
31. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, and Schinkel AH (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-1036.
32. von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, and Greenblatt DJ (2004) Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 32:800-804. (Pubitemid 38955608)
33. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
34. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366. (Pubitemid 30137063)
35. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.